- ►diabetesjournals.org DJ Drucker - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic
peptide (GIP) exert important effects on β-cells to stimulate glucose-dependent
insulin secretion. Both peptides also regulate β-cell proliferation and ... Cited by 283 - Related articles - All 13 versions
- Free from Publisher DM Kendall, MC Riddle, J Rosenstock, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg),
−0.6 ± 0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs.
placebo), yielding placebo-adjusted reductions of −1.0% (10 μg) and ... Cited by 543 - Related articles - All 11 versions
- ►endojournals.org B Ahren, M Landin-Olsson, PA Jansson, M … - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc The stimulation of insulin vs. inhibition of glucagon secretion in relation to
the antidiabetic action of glucagon-like peptide-1 (GLP-1) is not established.
Here, the influence of a 4-wk increase in circulating GLP-1 by inhibition ... Cited by 329 - Related articles - BL Direct - All 7 versions
- Free from Publisher RA DeFronzo, RE Ratner, J Han, DD Kim, MS … - Diabetes care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A triple-blind, placebo-controlled, 30-week study
at 82 US sites was performed with 336 randomized patients. In all, 272 patients
completed the study. The intent-to-treat population baseline was 53 ± 10 ... Cited by 637 - Related articles - All 6 versions
- Free from Publisher B Ahrén, R Gomis, E Standl, D Mills, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—In patients randomized to LAF237, baseline HbA 1c averaged 7.7 ± 0.1%
and decreased at week 12 (Δ = −0.6 ± 0.1%), whereas HbA 1c did not change
from a baseline of 7.9 ± 0.1% in patients given placebo (between-group ... Cited by 310 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46
± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms,
respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA ... Cited by 454 - Related articles - BL Direct - All 13 versions
M Zander, S Madsbad, JL Madsen, JJ Holst - The Lancet, 2002 - Elsevier 20 patients with type 2 diabetes were alternately assigned continuous
subcutaneous infusion of GLP-1 (n=10) or saline (n=10) for 6 weeks. Before (week
0) and at weeks 1 and 6, they underwent β-cell function tests ... Cited by 615 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent
glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on
the pancreatic β-cells, and inhibitory effects on gastrointestinal ... Cited by 154 - Related articles - BL Direct - All 5 versions
TP Vahl, DA D'Alessio - eid, 2004 - Informa Pharma Science It has been known for at least one century that agents secreted from the
intestine during meal absorption regulates glucose assimilation. Extensive
research during the past three decades has identified two gut hormones, ... Cited by 24 - Related articles - All 4 versions
- ►endojournals.org OG Kolterman, JB Buse, MS Fineman, E Gaines … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Despite the advent of new treatments, glucose control in the type 2 diabetes
population is unsatisfactory. AC2993 (synthetic exendin-4; exenatide), a novel
glucose-dependent insulinotropic agent, exhibited notable antidiabetic ... Cited by 275 - Related articles - BL Direct - All 6 versions
